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membrane fibrosis suggests its involvement in the underlyingConnective tissue growth factor and its regulation in the perito-
pathophysiologic mechanism(s).neal cavity of peritoneal dialysis patients.
Background. Connective tissue growth factor (CTGF) is a
fibrogenic cytokine that is highly expressed in wound healing
and fibrotic lesions. The role of transforming growth factor-
Fibrosis of the peritoneal membrane, characterized by(TGF-) in fibrosis is well documented, and the emerging un-
thickening of the basement membrane and submesothel-derstanding that its fibrogenic actions are mediated through
CTGF has provided an attractive target molecule for the modu- ial fibrosis, inevitably occurs with time in peritoneal dial-
lation of matrix overproduction in fibrotic disease. The involve- ysis (PD) patients [1–3]. It is thought that the major under-
ment of CTGF in the pathogenesis of peritoneal membrane lying causes are the constant exposure of the peritonealfibrosis in peritoneal dialysis (PD) patients has not been investi-
membrane to the hypertonic dextrose-based dialysategated, and so the aim of this study was to ascertain whether
and acute episodes of peritonitis. While the pathophysio-CTGF is produced in the peritoneal cavity of PD patients and
to investigate its regulation by cytokines. logic mechanisms characterizing peritoneal membrane
Methods. Reverse transcription-polymerase chain reaction fibrosis are not well defined, it most likely represents a
(RT-PCR), Northern blotting, and Western blotting were used
dysfunctional wounding response to the repeated insults.to study CTGF expression by cultured human peritoneal meso-
The profibrotic growth factor, transforming growththelial cells (HPMC) from peritoneal dialysis patients. Western
blotting was used to detect CTGF expression in spent perito- factor- (TGF-), is present within the peritoneal cavity
neal dialysate from patients with and without peritonitis. and is thought to be a key mediator of the fibrotic response
Results. RT-PCR analysis demonstrated the expression of [4–7]. Blocking TGF- bioactivity attenuates extracellu-CTGF mRNA in cultured primay HPMCs isolated from spent
lar matrix deposition and the progression of fibrosis inperitoneal effluent. The production of the major 36 to 38 kD
experimental models of renal disease [8], but long-termCTGF protein doublet by HPMC in addition to a 23 to 25
kD proteolytically processed form was confirmed by Western inhibition of TGF- in the clinical setting presents sev-
blotting. Several molecular weight forms of CTGF (18 to 38 eral theoretic problems. In addition to its profibrotic activ-
kD) were also detected by Western blotting in peritoneal dialy-
ity, TGF- plays a pivotal role as a modulator of immunesate, with levels markedly elevated during episodes of peritoni-
function and tumor growth, raising concern about thetis. Northern and Western blot analysis revealed that CTGF
mRNA and protein production by HPMC was up-regulated long-term consequences of its suppression [9, 10].
by TGF-, with mRNA levels significantly increasing above Connective tissue growth factor (CTGF), first identi-
the control (P  0.01). In contrast, platelet-derived growth fied in human umbilical vein endothelial cells, is chemo-
factor (PDGF), epidermal growth factor (EGF), and tumor
tactic and mitogenic for fibroblasts [11]. It is a cysteine-richnecrosis factor-alpha (TNF-) had no measurable effects on
36 to 38 kD peptide belonging to the recently describedCTGF mRNA expression.
Conclusion. These results are the first to demonstrate the CCN gene family [12]. CTGF’s properties include effects
production of CTGF by HPMC and its presence in the perito- on proliferation, migration, matrix production, angiogen-
neal cavity of PD patients. The marked increase in CTGF esis, adherence, and granulation tissue formation [13–19].levels by factors implicated in the development of peritoneal
Importantly, its stimulation of cell migration and matrix
production are mediated through TGF-, providing an
Key words: connective tissue growth factor, fibrosis, peritoneal dialysis. attractive target molecule for the modulation of matrix
overproduction in fibrotic disease [20].
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and skin [24]. The coordinate expression of TGF- has herent HPMC population of cells proliferated to form
a monolayer with features typical of cultured HPMCalso been documented in several of these pathologies
[23, 24]. Studies in various cell types, including natural and were uniformly positive for cytokeratins 8 and 18
and negative for macrophage and other leukocyte mark-rat kidney (NRK), human foreskin fibroblasts, NIH3T3
cells, glomerular visceral epithelial cells, and mesangial ers, as reported previously [33].
cells, have shown dramatic up-regulation of CTGF mRNA
Experimental designexpression by TGF- [14, 15, 21, 25, 26]. This involves
Smads, a family of intracellular signaling molecules [27]. All experiments were carried out in duplicate in sec-
ond-passage HPMC obtained from at least four differentA functional Smad binding site that is required but not
sufficient for TGF- induction of CTGF gene transcription, PD patients. The effect of cytokines was conducted fol-
lowing seeding of HPMC into 6-well plates (Nalge Nunchas been identified [28, 29]. In addition, a unique transcrip-
tional response element, previously termed TGFRE [30], International, Rochester, NY, USA). HPMC were cul-
tured to confluence, after which the growth medium wasis present in the CTGF promoter region and appears to
be important for basal expression in normal fibroblasts replaced with essentially serum-free culture medium
[0.5% (vol/vol) FCS] for 24 hours. Duplicate wells ofand elevated expression in scleroderma fibroblasts [28,
29]. CTGF expression is also induced in mesangial cells HPMC were then treated with 2 ng/mL TGF-, 2 ng/mL
tumor necrosis factor- (TNF-) (both from R&D Sys-exposed to high glucose [18, 31], and in fibroblasts by
advanced glycosylation end products [32], suggesting the tems, Minneapolis, MN, USA), 10 ng/mL epidermal
growth factor (EGF) (Becton Dickinson), or 10 ng/mLexistence of other induction pathways.
In this report, we demonstrate the inducible produc- platelet-derived growth factor (PDGF) (PeproTech,
Inc., Rocky Hill, NJ, USA), for 24 hours in fresh serum-tion of CTGF in human peritoneal mesothelial cells
(HPMC), and its presence in peritoneal effluent isolated deplete medium. Control cells were maintained in the
medium deplete of cytokines for the equivalent durationfrom nonperitonitis and peritonitis patients, suggesting
its involvement in the development of peritoneal mem- of treatment. Cellular RNA was extracted with RNAzol
B (Tel-Test, Inc., Friendswood, TX, USA) and levels ofbrane fibrosis.
CTGF mRNA assessed by Northern blot analysis. To
assess the effect of TGF- on HPMC CTGF protein
METHODS
levels, essentially the same culture conditions were used
Materials as stated above, except cultures were also coincubated
with or without 50 g/mL sodium heparin (DBL, Mel-[-32P] deoxycytidimine triphosphate (dCTP) (3000 Ci/
mmol/L) and polymerase chain reaction (PCR) oligonu- bourne, Victoria, Australia). Levels of CTGF were as-
sessed by Western blot analysis following heparin sepha-cleotide primers were obtained from GeneWorks (The-
barton, South Australia, Australia). Anti-CTGF poly- rose precipitation.
clonal antibody was raised against purified recombinant
RT-PCR analysishuman CTGF and supplied by FibroGen, Inc. (South
San Francisco, CA, USA). All other chemicals, unless Total RNA (1.6 g) per sample was converted to
cDNA with avian myeloblastosis virus (AMV) reverseotherwise stated, were purchased from Merck (Kilsyth,
Victoria, Australia) and Sigma Chemical Company (St. transcriptase using random primers, as per manufactur-
er’s instructions (Cat #A3500, Promega Corp., Madi-Louis, MO, USA).
son,WI, USA). cDNA was then subjected to “hot start”
Cell culture PCR amplification using 1.0 U Amplitaq Gold (Perkin
Elmer, Shelton, CT, USA), according to the supplier’sHPMC were isolated from spent peritoneal dialysate
obtained from patients without peritonitis, and cultured protocol. mRNA-specific oligonucleotide primers were
designed from published genomic sequences (GenBank)according to our published method [33]. Isolated cells
were placed into 25 cm2 flasks (Becton Dickinson, Frank- such that the recognition sites of the upstream and down-
stream primers resided in separate exons (Table 1). PCRlin Lakes, NJ, USA) precoated with 1 g/mL type I colla-
gen (Collaborative Biomedical, Bedford, MA, USA) and was performed for 23 cycles for glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), and 26 cycles for CTGFincubated overnight at 37C in 5% CO2 in Biorich 1 me-
dium (ICN Flow, Irvine, Scotland), supplemented with 10 (listed in Table 1), such that all products could be assayed
in the exponential phase of the amplification curve in ammol/L HEPES, 50 nmol/L hydrocortisone (Pharmacia &
Upjohn, Rydalmere, New South Wales, Australia), 4 thermal cycler (Corbett Research, Mortlake, New South
Wales, Australia). The PCR conditions were 95C formmol/L l-glutamine (CSL, Parkville, Victoria, Austra-
lia), 0.04 U/mL penicillin (CSL), 0.4 U/mL gentamicin 9 minutes to activate the polymerase, and each cycle
consisted of 1 minute at 94C, 1 minute at 62C (for(CSL), and 5% (vol/vol) fetal calf serum (FCS) (CSL).
Biorich 1 medium contains 15 mmol/L glucose. The ad- GAPDH) or 72C (for CTGF), and 1 minute at 72C.
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Table 1. Details of primers used for reverse transcription-polymerase chain reaction (RT-PCR) analysis
Target Accession number Sequence—sense primer Sequence—antisense primer Product
CTGF AL354866 5-CAT GTA ACT TTT GGT CAC ACT C-3 5-GAA TGT AAA GCT TGT CTG ATC G-3 485 bp
GAPDH X01677 5-CAC TGA CAC GTT GGC AGT GG-3 5-CAT GGA GAA GGC TGG GGC TC-3 417 bp
The synthetic oligonucleotides used in this study were primer pairs spanning the intron-exon boundaries of connective tissue growth factor (CTGF) and glyceralde-
hyde phosphate dehydrogenase (GAPDH).
This was followed by an additional extension step at min (BSA) for 2 hours at room temperature, filters were
72C for 1 minute. Control reactions were carried out probed with anti-CTGF antibody (0.1 g/mL) overnight
in parallel using nonreverse transcribed RNA, and on at 4C in the same buffer. Filters were washed in 0.1%
reaction mixtures in which the target RNA was omitted. (wt/vol) skim-milk powder, 0.1% (wt/vol) BSA, 0.4%
Amplification products were resolved by electrophoresis (vol/vol) Tween-20, in PBS, and incubated with an alka-
on a 2% (wt/vol) agarose gel (Progen, Darra, Queens- line phosphatase-conjugated anti-rabbit immunoglobu-
land, Australia) and poststained with SYBRGold (Mo- lin G (IgG) (Amersham Pharmacia Biotech), 1:5000 dilu-
lecular Probes, Eugene, OR, USA). Fluorescent PCR tion in blocking buffer for 1 hour at room temperature.
products were visualized by a FluorImager SF (Molecu- Immunoreactivity was detected with an ECF reagent
lar Dynamics, San Francisco, CA, USA). Oligonucleo- (Amersham Pharmacia Biotech) according to the manu-
tide primer sequences and the expected PCR product facturer’s instructions.
sizes are listed in Table 1.
Northern blot analysis
Sequencing
Total RNA (15 g) was electrophoresed through a
The CTGF PCR product was sequenced using the 1.5% (wt/vol) agarose gel containing 2.2 mol/L formalde-
Qiagen Dye terminator protocol (Qiagen Pty, Ltd., Clif- hyde, transferred onto Hybond-N nylon membranes
ton Hill, Victoria, Australia). The obtained sequences (Amersham Pharmacia Biotech) in 10  standard so-
were aligned with the published CTGF sequence using dium citrate (SSC) (1  SSC is 0.15 mol/L NaCl and
the Clustal X Multiple Sequence Alignment program. 0.015 mol/L sodium citrate, pH 7.0) and immobilized by
ultraviolet cross-linking [32]. Blots were prehybridizedHeparin sepharose precipitation and
in l mol/L NaCl, 1% (wt/vol) SDS, 10% (wt/vol) dextranWestern blot analysis
sulfate (Progen), 50% (vol/vol) formamide (ICN Bio-
Heparin sepharose precipitation and Western blotting
medicals), and 100 g/mL herring sperm DNA (Rocheprocedures used were as described in [31]. Briefly, CTGF
Diagnostics), at 42C for 6 hours. Hybridization was per-protein from HPMC cultures and spent peritoneal dialy-
formed in the same solution, additionally containing asate (25 mL/sample) was precipitated with heparin seph-
heat-denatured 485 bp [-32P]dCTP-labeled cDNA probearose CL-6B (Amersham Pharmacia Biotech, Inc., Pisca-
for CTGF. The probe was made using a gel-purified PCRtaway, NJ, USA) with end-over-end mixing for 16 hours
product of CTGF, which was [-32P]dCTP-labeled usingat 4C. HPMC cell layer fractions were previously ex-
the GIGA prime random labeling kit (GeneWorks).tracted at 4C for 30 minutes in 1% (vol/vol) Triton X-100,
Blots were washed in 2  SSC and 0.1% (wt/vol) SDS,50 mmol/L Tris-HCl, pH 7.4, and a cocktail of broad-
once at 42C and once at 55C, for 30 minutes each, withspectrum protease inhibitors (Cat. #1836153, Roche Di-
a final high stringency wash in 0.1  SSC and 0.1% (wt/agnostics, Castle Hill, New South Wales, Australia). Fol-
vol) SDS at 55C for 30 minutes. To allow normalizationlowing a bead wash in 1000  volumes of 150 mmol/L
of mRNA signals, the same filters were stripped usingNaCl, 50 mmol/L Tris-HCl, pH 7.5, 1% (vol/vol) Tri-
boiling stripping solution [0.1  SSC and 0.1% (wt/vol)ton X-100, 0.1% (wt/vol) sodium dodecyl sulfate (SDS)
SDS] and reprobed with a 417 bp [-32P] dCTP-labeledand 2 mmol/L ethylenediaminetetraacetic acid (EDTA),
PCR-generated DNA fragment of GAPDH. The samebinding proteins were eluted by boiling for 5 minutes in
hybridization and washing procedures were used as de-NuPAGE lithium salt of dodecyl sulfate (LDS) sample
scribed above. Signals were analyzed using the Phos-buffer (Invitrogen Corporation, Carlsbad, CA, USA) un-
phorImager SF and quantified using ImageQuant soft-der nonreducing conditions. Proteins were resolved on
ware (Molecular Dynamics).10% NuPAGE Bis-Tris gels (Novex) and electrophoreti-
cally transferred for 11⁄2 hours at 100 V to nitrocellulose
Statistical analysis(Schleicher & Schuell, Keene, NH). Following blocking
Data is expressed as mean 	 SD and differences be-in 150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.4, 0.2%
(vol/vol) Tween-20 and 2% (wt/vol) bovine serum albu- tween two groups were evaluated using a paired t test.
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protein doublet was clearly visible (Fig. 3B). Sodium
heparin, however, had no effect on the intensity of bands
in the cell layer (Fig. 3A). The 25 kD band in the cell
layer and the 23 and 25 kD protein species in the medium
fraction most likely represent proteolytically processed
forms of CTGF that contain a heparin binding site.
These results demonstrate that intact as well as proteo-
lytically processed forms of CTGF are produced by HPMC
and that a proportion of CTGF remains cell associated,
but can be displaced by heparin. Thus, in the peritoneal
cavity of PD patients, HPMC may be a major source of
this important fibrogenic cytokine.
Fig. 1. Variable expression of connective tissue growth factor (CTGF) CTGF protein is present in the peritoneal cavity and
mRNA in cultured human peritoneal mesothelial cells (HPMC) derived is increased during peritonitisfrom five patients (lanes 1 to 5) on peritoneal dialysis. (A) Total RNA
was isolated and CTGF mRNA expression analyzed by reverse tran- To investigate the presence of CTGF in the peritoneal
scription-polymerase chain reaction (RT-PCR). Water control (W) and
cavity of PD patients, CTGF Western blotting of spentnon reverse-transcribed RNA control (R). (B ) Results were compared
peritoneal dialysate was carried out. Following precipita-to the expression levels of the housekeeping gene, glyceraldehyde phos-
phate dehydrogenase (GAPDH). tion with heparin sepharose, the major protein species
detected in peritoneal dialysate obtained from four indi-
vidual patients was a doublet of 36 to 38 kD. A lower-
molecular-weight protein species of 23 kD was also de-RESULTS
tected in the spent peritoneal effluent (Fig. 4A). The
HPMC express CTGF mRNA intact 36 to 38 kD peptide in the peritoneal dialysate is
CTGF mRNA expression by HPMC was examined by identical to the intact form of CTGF produced by HPMC
RT-PCR analysis. Total RNA was isolated from cultured (Fig. 3), whereas the 23 kD species most likely represents
HPMC and RT-PCR performed using an oligonucleotide the proteolytically processed form of CTGF that is also
primer pair spanning the intron-exon boundaries of present in the HPMC medium fraction (Fig. 3B). West-
CTGF (Table 1). Results show the positive expression ern blotting using a normal rabbit serum control con-
of CTGF mRNA by HPMC derived from five individual firmed the specificity of the CTGF antibody (Fig. 4B).
PD patients, albeit at variable levels when compared to Western blot analysis of spent peritoneal dialysate iso-
the GAPDH loading control (Fig. 1). The specificity of lated from patients with peritonitis revealed an increase
the CTGF primers was confirmed by the absence of a in CTGF levels in the peritoneal cavity (Fig. 4 C and
signal in both the water and nonreverse transcribed RNA D). In all patients tested, peritonitis was associated with
controls. an increase in both the intact form of CTGF and proteo-
The identity of CTGF was confirmed by sequencing lytically processed CTGF reactive fragments ranging in
the RT-PCR product from cultured HPMC obtained size from 18 to 25 kD. Semiquantitative analysis revealed
from three individual patients. Data presented represent that CTGF levels in pretreated peritonitis patients rose
the CTGF sequence within exon 5 of the CTGF gene three- to fourfold above basal levels. As peritonitis re-
and shows a 100% homology to the published human solved with successful treatment, the levels of CTGF
CTGF sequence in all patients analyzed (Fig. 2). returned to baseline.
Collectively, the above results demonstrate the pres-
CTGF protein is synthesized by HPMC ence of the fibrogenic cytokine CTGF in the peritoneal
The synthesis of CTGF protein by HPMC was estab- cavity of PD patients and that the levels of CTGF in-
lished with Western blotting, using a polyclonal antibody crease during the inflammatory phase of peritonitis.
raised against recombinant human CTGF. Following
CTGF mRNA and protein is up-regulated by TGF-precipitation with heparin sepharose, the major protein
species detected in the cell layer was a doublet of 36 to To determine whether cytokines present in the perito-
38 kD, corresponding to the intact form of CTGF, and neal cavity may regulate the expression of CTGF mRNA
a minor species of 25 kD (Fig. 3A). In the medium in HPMC, confluent cells at second passage were cul-
fraction, the intact form of CTGF (36 to 38 kD) was also tured in low serum culture medium (0.5%) for 24 hours,
identified as well as a minor 23 kD protein band (Fig. and then treated with either 2 ng/mL TGF-, 2 ng/mL
3B). Addition of 50 g/mL sodium heparin to HPMC TNF-, 10 ng/mL EGF, or 10 ng/mL PDGF for 24 hours.
cultures for 24 hours increased the presence of intact A control using low serum culture medium (0.5%) was
also included in the experiment. These experiments wereCTGF protein in the culture medium, and a 23 to 25 kD
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Fig. 2. Confirmation of the human connec-
tive tissue growth factor (CTGF) reverse tran-
scription-polymerase chain reaction (RT-PCR)
product derived from human peritoneal meso-
thelial cells (HPMC) in three individual pa-
tients. The RT-PCR product was isolated and
sequenced as described in the Methods sec-
tion. Results are compared to the published
CTGF cDNA sequence coding for the mature
CTGF peptide (top line). Sequence alignment
shows that the HPMC RT-PCR products have
100% sequence identity to the published se-
quence.
without 50 g/mL sodium heparin. Following precipita-
tion of the culture medium with heparin sepharose,
Western blotting revealed that TGF- increased the lev-
els of full-length CTGF (36 to 38 kD) in HPMC culture
medium (86% increase with TGF- alone, 127% in-
crease with TGF- in the presence of heparin) (Fig. 6).
Furthermore, the TGF- induced increase in 36 to 38
kD CTGF protein levels were more marked in the pres-
ence of sodium heparin [12-fold increase with TGF-
plus heparin (lane 4) relative to no treatment (lane 1)], as
Fig. 3. Connective tissue growth factor (CTGF) protein is produced
well as the 23 to 25 kD proteolytically processed CTGFby human peritoneal mesothelial cells (HPMC). Western blot analysis
of cultured HPMC revealed the presence of the intact CTGF doublet doublet.
(36 to 38 kD) as well as CTGF fragments of lower molecular weight
(23 and 25 kD) in the cell layer (A) and medium fractions (B). Treatment
of cultures with sodium heparin (SH) resulted in a marked increase DISCUSSION
in CTGF in the medium fraction when compared to control (
SH).
Western results are directly comparable since samples are equivalent In this report we demonstrate the production of CTGF
for volume and duration of treatment. by HPMC, and its presence in peritoneal effluent from
PD patients, suggesting a role for this cytokine in the
peritoneal cavity. This has not previously been studied.
CTGF is a key promoter of extracellular matrix deposi-performed in duplicate HPMC cultures isolated from five
tion and wound healing, and thus is an important contrib-individual patients. Following isolation of total RNA,
utor to the maintenance of connective tissue structurethe levels of CTGF mRNA were analyzed by Northern
and function [35]. HPMCs, which are key players in theblotting using a 32P-labeled CTGF RT-PCR product. The
synthesis and maintenance of the peritoneal membranechanges in CTGF mRNA expression in response to the
[36], express CTGF mRNA (Figs. 1 and 2) and the pro-cytokine treatments were quantified relative to the house-
tein (Fig. 3), lending support to a tissue maintenance rolekeeping gene GAPDH. Exogenous exposure to TGF-
for this cytokine within the peritoneum. Importantly, thesignificantly increased the expression of CTGF mRNA
novel finding of its up-regulation during peritonitis, and3.8 1.3-fold above the control (Fig. 5 A and B), whereas
its induction in HPMC by TGF-, also supports a roleTNF-, EGF, and PDGF had no measurable effect (re-
for CTGF as a potentially critical component in the patho-sults not shown).
genesis of peritoneal membrane fibrosis in PD patients.To determine whether the increase in CTGF mRNA
Western blot analysis demonstrated the synthesis ofby TGF- was also associated with an increase in CTGF
36 to 38 kD and 23 to 25 kD CTGF reactive proteinprotein levels, confluent HPMC at second passage were
doublets (Fig. 3). The 36 to 38 kD form of CTGF hascultured in serum depleted culture medium for 24 hours,
been reported in various cell types, including mesangial,and then treated with or without 2 ng/mL TGF-. During
treatment the medium was also supplemented with or vascular endothelial, and fibroblast cells [11, 15, 31, 37].
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Fig. 5. Transforming growth factor- (TGF-) increases the expres-
sion of connective tissue growth factor (CTGF) mRNA in human perito-
neal mesothelial cells (HPMC). A representative Northern blot shows
CTGF mRNA expression in HPMCs obtained from two donors (1 and
2) (A). Results were compared to the expression levels of the housekeep-
ing gene, glyceraldehyde phosphate dehydrogenase (GAPDH) and show
that CTGF mRNA was induced by 2 ng/mL TGF- () when compared
to the no treatment control (
). Treatment of cells from five individual
patients with TGF- showed a statistically significant increase in theFig. 4. Connective tissue growth factor (CTGF) protein is present in
mRNA levels of CTGF (B). *P  0.01.the peritoneal cavity of peritoneal dialysis patients. Spent peritoneal
dialysate was examined from four individual patients (lanes 1 to 4) for
the presence of CTGF protein by Western blot analysis. Results show
variable levels of intact CTGF protein (36 to 38 kD) and a proteolytically
processed CTGF peptide fragment (23 kD) in the peritoneal dialysate
samples (A). The specificity of the CTGF antibody (CTGF) was con-
firmed by the absence of CTGF bands with normal rabbit serum (NRS)
(B). During peritonitis, CTGF protein levels are elevated in the perito-
neal cavity (C and D ). Spent peritoneal dialysate was examined from
several individuals before, during, and after peritonitis by Western blot
analysis. The preperitonitis samples were obtained weeks to months
before the episode of peritonitis. The representative results show that
the levels of intact and proteolytic CTGF fragments (18 to 25 kD) are
elevated during peritonitis but then fall back to basal levels following
treatment. Abbreviations are: Pre, preperitonitis; D, number of days
on peritonitis treatment; Post, postperitonitis. Dialysate samples of iden-
tical volume and from spent dialysate with identical dwell times were
analyzed so that Western blots gave a semiquantitative comparison of
the concentration of CTGF between the samples.
Fig. 6. Transforming growth factor- (TGF-) increases the produc-
An 18 kD form has been reported in cultured rat mesan- tion of connective tissue growth factor (CTGF) protein in human perito-
neal mesothelial cells (HPMC). A representative Western blot showsgial cells [31] and in a human breast cancer cell line
an increase in the amount of secreted CTGF in the presence () of 2(Hs578T), the latter also producing a 24 kD anti-CTGF
ng/mL TGF-. This effect is more pronounced in the presence () of
reactive peptide [38]. Glycosylation studies in Hs578T sodium heparin.
cells have demonstrated that CTGF is composed of a 30
kD protein core containing 2 to 8 kD of N-linked sugars
[38]. Thus, the 36 to 38 kD form of CTGF represents rin (Fig. 3B) suggests that the majority of CTGF synthe-
sized by HPMC remains cell and/or extracellular matrixN-glycosylation variants of the intact CTGF peptide,
while the 23 to 25 kD form of CTGF produced by HPMC associated. In support of this notion, CTGF synthesized
by human foreskin fibroblasts [37] and mesangial cellmost likely represent proteolytically processed CTGF
fragments that can bind heparin. cultures [31] has been shown as a cell-associated cyto-
kine, with the latter study illustrating an 80% cell layerThe marked increase in appearance of CTGF in HPMC
culture medium following incubation with sodium hepa- association. The inability to detect concomitant changes
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in cell layer CTGF levels with sodium heparin treatment ibility of CTGF mRNA and protein by TGF- (Fig. 5)
is likely due to the nature of the sample harvesting proce- in HPMC, confirming the ability of CTGF to be regulated
dure prior to Western blotting (Fig. 3A). Here, the cell in a tissue constantly undergoing a wounding response.
layers are washed twice following the removal of me- Activation of the peritoneal mesothelial cells is likely
dium, a process that would likely remove a large propor- to contribute to the elevated levels of CTGF during
tion of cell layer associated CTGF. peritonitis, although other potential sources of CTGF
The above results indicate that CTGF produced by exist in the peritoneal membrane, including vascular en-
HPMC is similar to that characterized in other culture dothelial cells and peritoneal fibroblasts. Regardless of
systems, and may play a key role in peritoneal membrane the source, our findings provide strong evidence for the
function. In support of the latter, CTGF protein was involvement of CTGF in the pathophysiology of perito-
detectable in the peritoneal dialysate isolated from PD neal membrane fibrosis in PD patients.
patients (Fig. 4 A and B). This implies that CTGF is a These findings build a firm foundation upon which
relatively abundant cytokine that is able to act in areas future research will be based, and we propose to further
distant from its site of synthesis within the peritoneal investigate the regulation and function of CTGF within
cavity. Western blotting revealed the presence of the the peritoneal cavity using recombinant protein. A key
intact 36 to 38 kD CTGF doublet in addition to the 23 aspect of this will be determining the site of CTGF action
to 25 kD fragments as previously demonstrated in in the peritoneal cavity. While this may be, in part, the
HPMC, as well as an 18 kD species. Immunologic charac- peritoneal mesothelial cells themselves, as they have the
terization of numerous biologic fluids, including amni- ability to produce fibrous matrix molecules, it is also
otic, follicular, and peritoneal fluids, and in normal and likely that an important target of CTGF will be the peri-
pregnancy serum, has shown the presence of 18, 24, 32, toneal fibroblasts. This research will allow further insight
and 38 kD forms of CTGF [38]. Various molecular- into understanding peritoneal membrane physiology,
weight peptide fragments immunologically reacting with which, in turn, will benefit those on peritoneal dialysis.
anti-CTGF have also been demonstrated in porcine uter- The discovery of CTGF within the peritoneal cavity will
ine secretions, including 10, 16, 18, and 20 kD heparin- also assist in the development of novel therapeutic agents
binding molecules [39, 40]. Although the structure and that target CTGF, in turn interrupting the maladaptive
biologic role of these CTGF fragments is unknown, sev- fibrotic responses to peritoneal membrane injury in PD
eral studies carried out with an isolated 10 kD CTGF patients.
fragment have shown its mitogenic activity for DNA
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